Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03160183
Other study ID # LCCC 1424
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 2016
Est. completion date October 1, 2020

Study information

Verified date December 2020
Source UNC Lineberger Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to identify important associations between complete and comprehensive clinical, laboratory, and genomic data derived from patients and tumor specimens, with prospectively recorded clinical outcomes. The investigators also hope to move beyond simple risk factor associations as previously described, to develop a composite score specifically for KS recurrence or progression, analogous to widely used risk scores that are used to direct up-front treatment of other cancers. In so doing, the investigators will draw on extremely granular data to prospectively identify patients who are most likely to benefit from new treatments.


Description:

This is a prospective, nonrandomized, open-label, single arm, cohort study of pathologically confirmed HIV-associated KS patients initiating chemotherapy in Malawi. The primary objective of this study is to estimate the complete response rate (CR by ACTG criteria) at 48 weeks. This will be done both overall and by chemotherapy (BV or not BV) treatment group. Secondary objectives are to estimate PFS and OS for both overall and by chemotherapy treatment group. Exploratory objectives include the investigation of: select clinical variables and laboratory biomarkers among HIV-associated KS patients and their possible association with response, PFS, and OS; the histopathology of KSHV-associated lymphoproliferative diseases among HIV-associated KS patients; KSHV strains in tumor biopsies, PBMC and plasma, and KSHV gene expression characteristics between KS that develops on and off ART. The investigators plan to accrue 200 HIV-associated KS patients at a rate of approximately 50 patients per year. Approximately half of the patients will receive BV chemotherapy treatment. An important factor for this study's size is that it will be comparable to or exceed the size of other important KS cohort studies, which have demonstrated significant differences in outcomes based on gender or baseline KSHV DNA levels. The investigators want to show that there are definable biologic and clinical subsets within the HIV-associated KS population, and that identifying these subsets will have direct relevance to more effective treatment strategies for these patients.


Recruitment information / eligibility

Status Completed
Enrollment 157
Est. completion date October 1, 2020
Est. primary completion date October 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Histologically confirmed KS initiating chemotherapy at Lighthouse Trust or the Kamuzu Central Hospital (KCH) Cancer Clinic - HIV positive (confirmed at any time point prior by local standard of care assay) on or off ART - Age =18 years - Residence <200 kilometers from KCH - Able to understand and comply with study procedures for the entire length of the study - Subject able to understand and provide written consent in English or Chichewa Informed consent reviewed and signed by patient Exclusion Criteria: - Failure to meet inclusion criteria listed above. - Specifically, pregnancy and breastfeeding are not exclusion criteria given the observational nature of the study with diagnostic and treatment interventions administered according to local standards of care. - KS relapse disease as defined by a prior KS diagnosis within 1 year prior to enrollment.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Malawi UNC Project Lilongwe
Malawi UNC Project, Lighthouse Trust Lilongwe

Sponsors (2)

Lead Sponsor Collaborator
UNC Lineberger Comprehensive Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

Malawi, 

Outcome

Type Measure Description Time frame Safety issue
Other The clinical variables and laboratory biomarkers among HIV-associated KS patients and their possible association with response, PFS, and OS The prevalence and nature of lymphoproliferative diseases among HIV-associated KS patients 48 weeks
Other The histopathology of KSHV-associated lymphoproliferative diseases among HIV-associated KS patients KSHV gene expression characteristics for HIV-associated KS that develops on and off antiretroviral therapy (ART) 48 weeks
Other The kind of KSHV strains in tumor biopsies, PBMC and plasma Viral genome features of HIV-associated KS 48 weeks
Other The KSHV gene expression characteristics between KS that develops on and off ART To describe KSHV gene expression characteristics between KS that develops on and off ART 48 weeks
Primary Estimate the complete response rate (CR) at 48 weeks of HIV-associated KS patients overall and by BV treatment group. the assessment of a patient's response (CR) to chemotherapy at 48 weeks by ACTG criteria 48 weeks
Secondary Estimate the Progression Free Survival (PFS) in HIV-associated KS patients overall and by bleomycin-vincristine (BV) treatment group PFS which will be defined as the time from treatment initiation until disease progression or death 48 weeks
Secondary Estimate OS in HIV-associated KS patients overall and by BV treatment group To estimate OS in HIV-associated KS patients overall and by BV treatment group 48 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Active, not recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2